See more : Nuvation Bio Inc. (NUVB) Income Statement Analysis – Financial Results
Complete financial analysis of Alpine Immune Sciences, Inc. (ALPN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alpine Immune Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- The Nihon Seima Co.,Ltd. (3306.T) Income Statement Analysis – Financial Results
- Navient Corporation (0K5R.L) Income Statement Analysis – Financial Results
- FOCI Fiber Optic Communications, Inc. (3363.TWO) Income Statement Analysis – Financial Results
- Digital Realty Trust, Inc. (0I9F.L) Income Statement Analysis – Financial Results
- Terai Tea Company Limited (TERAI.BO) Income Statement Analysis – Financial Results
Alpine Immune Sciences, Inc. (ALPN)
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.88M | 30.06M | 23.44M | 9.34M | 1.74M | 705.00K | 1.73M | 2.95M | 492.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 80.90M | 597.00K | 620.00K | 27.19M | 35.85M | 28.97M | 10.63M | 143.00K | 66.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -22.03M | 29.47M | 22.82M | -17.85M | -34.11M | -28.27M | -8.90M | 2.81M | 426.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -37.41% | 98.01% | 97.36% | -191.22% | -1,960.17% | -4,009.22% | -513.86% | 95.15% | 86.59% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.90M | 70.24M | 58.74M | 27.19M | 35.85M | 28.97M | 10.63M | 23.32M | 16.05M | 12.20M | 13.14M | 7.10M |
| General & Administrative | 22.22M | 17.97M | 14.56M | 10.90M | 9.47M | 8.36M | 6.08M | 8.59M | 6.84M | 2.29M | 2.14M | 1.93M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.22M | 17.97M | 14.56M | 10.90M | 9.47M | 8.36M | 6.08M | 8.59M | 6.84M | 2.29M | 2.14M | 1.93M |
| Other Expenses | 0.00 | -97.00K | -4.00K | 1.33M | 812.00K | 1.20M | 0.00 | 0.00 | 80.00K | 296.34K | 0.00 | 150.94K |
| Operating Expenses | 103.13M | 88.21M | 73.30M | 38.08M | 45.31M | 37.33M | 16.71M | 31.90M | 22.90M | 14.49M | 15.28M | 9.03M |
| Cost & Expenses | 103.13M | 88.21M | 73.30M | 38.08M | 45.31M | 37.33M | 16.71M | 31.90M | 22.90M | 14.49M | 15.28M | 9.03M |
| Interest Income | 11.85M | 3.29M | 259.00K | 245.00K | 1.25M | 1.30M | 542.00K | 439.00K | 80.00K | 0.00 | 10.00K | 0.00 |
| Interest Expense | 98.00K | 476.00K | 816.00K | 775.00K | 338.00K | 319.00K | 152.00K | 0.00 | 0.00 | 845.10K | 931.00K | 694.07K |
| Depreciation & Amortization | 576.00K | 3.19M | 255.00K | 1.58M | 2.06M | 388.00K | 241.00K | 143.00K | 66.00K | 86.44K | 219.00K | 212.03K |
| EBITDA | -43.67M | -54.96M | -49.60M | -27.17M | -41.51M | -35.33M | -14.19M | -31.90M | -22.90M | -14.10M | -15.05M | -8.67M |
| EBITDA Ratio | -74.18% | -182.80% | -211.59% | -291.07% | -2,385.86% | -5,011.49% | -819.82% | -1,081.42% | -4,654.07% | 0.00% | 0.00% | 0.00% |
| Operating Income | -44.25M | -58.15M | -49.86M | -28.75M | -43.57M | -37.83M | -14.97M | -31.90M | -22.90M | -14.49M | -15.28M | -9.03M |
| Operating Income Ratio | -75.16% | -193.41% | -212.68% | -307.97% | -2,504.25% | -5,365.96% | -865.05% | -1,081.42% | -4,654.07% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 12.17M | 2.72M | -561.00K | 803.00K | 1.72M | 977.00K | 6.99M | 439.00K | 80.00K | -548.76K | -921.00K | -543.14K |
| Income Before Tax | -32.08M | -55.43M | -50.42M | -27.95M | -41.85M | -36.85M | -7.98M | -31.46M | -22.82M | -15.04M | -16.20M | -9.57M |
| Income Before Tax Ratio | -54.49% | -184.38% | -215.07% | -299.37% | -2,405.29% | -5,227.38% | -461.18% | -1,066.54% | -4,637.80% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 103.00K | 2.33M | -87.00K | -6.00K | 682.00K | -366.00K | -200.00K | -143.00K | -66.00K | 1.14M | 941.00K | 845.01K |
| Net Income | -32.18M | -57.76M | -50.33M | -27.94M | -42.53M | -36.49M | -7.78M | -31.46M | -22.82M | -15.04M | -16.20M | -9.57M |
| Net Income Ratio | -54.66% | -192.13% | -214.70% | -299.30% | -2,444.48% | -5,175.46% | -449.62% | -1,066.54% | -4,637.80% | 0.00% | 0.00% | 0.00% |
| EPS | -0.64 | -1.73 | -1.98 | -1.34 | -2.32 | -2.63 | -1.20 | -8.12 | -9.74 | -6.59 | -7.10 | -4.20 |
| EPS Diluted | -0.64 | -1.73 | -1.98 | -1.34 | -2.32 | -2.63 | -1.20 | -8.12 | -9.74 | -6.59 | -7.10 | -4.20 |
| Weighted Avg Shares Out | 50.00M | 33.44M | 25.48M | 20.83M | 18.36M | 13.85M | 6.48M | 3.87M | 2.34M | 2.28M | 2.28M | 2.28M |
| Weighted Avg Shares Out (Dil) | 50.00M | 33.44M | 25.48M | 20.83M | 18.36M | 13.85M | 6.48M | 3.87M | 2.34M | 2.28M | 2.28M | 2.28M |
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Drug maker Alpine Immune Sciences (NASDAQ: ALPN ) got a $4.9 billion buyout offer from Vertex Pharmaceuticals (NASDAQ: VRTX ) after getting good news on a new drug. Povetacicept, an autoimmune drug, won a successful Phase 2 review from the...
Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)
Alpine Immune Sciences Inc (NASDAQ: ALPN) is up 35% on Thursday after Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said it will acquire the biotechnology company for $65 per share. Is Alpine Immune stock fairly valued at $65?
Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)
Alpine Immune Sciences Inc (NASDAQ: ALPN) is up 35% on Thursday after Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said it will acquire the biotechnology company for $65 per share. Is Alpine Immune stock fairly valued at $65?
Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
Vertex Pharmaceuticals Inc.'s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company's rare-disease franchise, analysts said Thursday.
Alpine Immune Sciences soars on $4.9bn Vertex takeover
Alpine Immune Sciences Inc shares continued higher in pre-market trading, after soaring on Wednesday following news of the firm's US$4.9 billion takeover by Vertex Pharmaceuticals Incorporated. Shares climbed 36.3% to US$64.10 before the market opened, adding to Wednesday's 20.8% gain.
Alpine Immune Sciences soars on $4.9bn Vertex takeover
Alpine Immune Sciences Inc shares continued higher in pre-market trading, after soaring on Wednesday following news of the firm's US$4.9 billion takeover by Vertex Pharmaceuticals Incorporated. Shares climbed 36.3% to US$64.10 before the market opened, adding to Wednesday's 20.8% gain.
Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch
Vertex Pharmaceuticals (VRTX) will acquire clinical-stage immunotherapy company Alpine Immune Sciences (ALPN) in a deal valued at around $4.9 billion, both companies said Wednesday.
Shareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with Vertex
MILWAUKEE , April 10, 2024 /PRNewswire/ -- Ademi LLP is investigating Alpine (Nasdaq: ALPN) for possible breaches of fiduciary duty and other violations of law in its transaction with Vertex. Click here to learn how to join the https://www.ademilaw.com/case/alpine-immune-sciences-inc or...
Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal
Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.
ALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alpine Immune Sciences, Inc. (NASDAQ: ALPN) to Vertex Pharmaceuticals Incorporated for $65.00 per share is fair to Alpine shareholders. Halper Sadeh encourages Alpine shareholders...
Source: https://incomestatements.info
Category: Stock Reports